


ENSEMBLE THERAPEUTICS

Ensemble is developing a novel class of therapeutics, called Ensemblins™, which open up new ways to treat diseases by addressing drug targets that are currently inaccessible with conventional small molecule drugs. With its proprietary DNA-programmed drug discovery platform, Ensemble is the first company to successfully and reliably engineer synthetic macrocycle drugs. Ensemble has made strong progress in developing a pipeline of macrocycle product candidates, and is pursuing a business strategy to develop Ensemblins through its own internal efforts and through partnerships. Ensemble has a strong core foundation, including an experienced management team and solid financial resources.

ENSEMBLINS™: A NEW THERAPEUTIC CLASS

Ensemblins are a new class of drugs in an emerging therapeutic space between small molecules and biologics with drug compounds capable of addressing historically challenging targets. Ensemblins are designed with unique macrocycle structures to incorporate high levels of affinity and specificity but to stretch the limits of small molecules through the potential to bind to targets only addressable today with biologics.



ENSEMBLE PRODUCT PIPELINE

Ensemble is pursuing proprietary discovery and development programs in inflammation, oncology, pain and diabetes, focusing on Ensemblins that inhibit protein-protein or protein-peptide interactions.

Ensemble Pipeline					
Target	Discovery	Lead Optimization	Preclinical	Phase 1	Phase 2
Inflammation #1					
Oncology					
Diabetes					
Inflammation #2					
Pain					

In addition to its own programs, Ensemble is making rapid progress with its partners, Bristol-Myers Squibb and Pfizer, to develop Ensemblins against a number of high-value drug targets in multiple therapeutic areas.

BENEFITS OF ENSEMBLINS:

Distinct pharmaceutical properties:

Ensemblins have small molecule drug-like bioavailability enabling oral administration.

Target affinity and selectivity:

Ensemblins can bind to protein targets with surfaces that are not addressed by small molecules, opening up a range of unexploited targets.

Versatility:

Ensemblins can bind to a variety of targets for diverse disease indications (e.g., inflammation, immune modulators, cancer).

UNIQUE FEATURES OF MACROCYCLE DRUGS

Macrocyclic drugs have unique features to address more difficult drug discovery targets such as those involving protein-protein interactions, both inside and outside cells including the potential to bind to disease relevant proteins and greater ability to bind selectively to extended protein surfaces.

ENSEMBLIN PRODUCT PLATFORM: DNA-PROGRAMMED CHEMISTRY (DPC™)

The company's unique capabilities for discovering and developing Ensemblins is derived from its proprietary DNA-Programmed Chemistry (DPC™) platform which is capable of synthetically engineering macrocycle compounds. The DPC platform extends beyond the limits of traditional small molecule drug discovery enabling unmatched capabilities to successfully and reliably generate synthetic macrocyclic drug candidates. The value of DPC lies in the ability to control chemical reactivity through programming.

Ensemble has built a library of over 500,000 macrocyclic Ensemblins and is on track to deliver over one million macrocycles in 2010, the largest set of compounds ever assembled in the pharmaceutical industry.

HIGH-VALUE COLLABORATIONS

The company will create value through both a proprietary pipeline and the application of the Ensemblin platform in developing drugs against protein-protein interaction targets on behalf of its collaborators, supporting a high potential value for the Ensemblin platform.

During 2009, Ensemble established exclusive drug discovery alliances with **Bristol-Myers Squibb** and **Pfizer** to develop Ensemblins against certain high-value targets. Ensemble receives license fees, research funding, milestones and royalties on sales of products under both alliances.

COMPANY BACKGROUND

Ensemble was founded in 2004 and has assembled an experienced management team with pharmaceutical and diagnostic industry backgrounds, plus a strong set of investors, including Flagship Ventures, Arch Venture Partners, CMEA, Harris & Harris, and Boston University. Ensemble has raised \$32 million in two rounds of equity financing in 2004 and 2007.

Ensemble employs approximately 30 employees, primarily Ph.D. level scientists, all located in Cambridge, Massachusetts.

Ensemble has an extensive patent portfolio, including an exclusive, worldwide license from Harvard University to its DNA-Programmed Chemistry platform invented by Professor David Liu.

MANAGEMENT TEAM

Michael Taylor, Ph.D.

CEO, formerly Pfizer R&D

Nicholas Terrett, Ph.D.

CSO, formerly Pfizer R&D

David Livingston, Ph.D.

SVP Biology, formerly Vertex, Praelux, Genzyme

Stephen Hale, Ph.D.

VP Biochemistry & Screening, formerly Praecis

Andrea Szekely-Hill, CPA

Controller and Director of Operations, formerly Deloitte

BOARD OF DIRECTORS

Noubar Afeyan

Managing Partner, Flagship Ventures

Jean-Jacques Bienaime

CEO, BioMarin Pharmaceutical, Inc.

Douglas Cole

General Partner, Flagship Ventures

Robert Nelsen

Managing Director, Arch Venture Partners

Anna Protopapas

SVP, Millennium Pharmaceuticals, Inc.

Michael Taylor

CEO, Ensemble Therapeutics Corp.

CONTACT

Michael D. Taylor, Ph.D., CEO

Ensemble Therapeutics Corp.

99 Erie Street, Cambridge, MA 02139

mtaylor@ensembletx.com

617.492.6977 x233